Roche Stock Earnings Estimates Cut by Erste Group Bank

Roche Holding AG (OTCMKTS:RHHBY) – Erste Group Bank lowered their FY2026 EPS estimates for Roche in a note issued to investors on Thursday, October 8th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings per share of $3.05 for the year, down from their prior forecast of $3.14. The consensus estimate for Roche’s current full-year earnings is $3.03 per share. Erste Group Bank also issued estimates for Roche’s FY2027 earnings at $3.31 EPS.

A number of other research firms have also weighed in on RHHBY. Royal Bank Of Canada started coverage on shares of Roche in a report on Tuesday, September 8th. They set an “outperform” rating for the company. HSBC reaffirmed a “hold” rating on shares of Roche in a research note on Thursday, September 10th. Zacks Research upgraded shares of Roche from a “strong sell” rating to a “hold” rating in a report on Monday, August 24th. Finally, Morgan Stanley raised shares of Roche from an “equal weight” rating to an “overweight” rating and set a $63.00 price objective for the company in a research report on Friday, August 7th. Six investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Roche currently has a consensus rating of “Moderate Buy” and an average price target of $60.00.

Roche Price Performance

OTCMKTS RHHBY opened at $54.10 on Tuesday. The company’s fifty day simple moving average is $54.90 and its 200-day simple moving average is $52.59. Roche has a 52 week low of $40.07 and a 52 week high of $60.85. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.23 and a quick ratio of 0.95.

Institutional Investors Weigh In On Roche

Hedge funds and other institutional investors have recently bought and sold shares of the business. Opal Capital LLC bought a new stake in shares of Roche in the first quarter worth $4,448,000. S&CO Inc. raised its holdings in Roche by 163.0% in the first quarter. S&CO Inc. now owns 140,551 shares of the company’s stock valued at $6,880,000 after acquiring an additional 87,107 shares in the last quarter. North Star Asset Management Inc. acquired a new stake in Roche in the second quarter valued at $1,351,000. Puzo Michael J bought a new position in Roche during the 2nd quarter valued at $1,229,000. Finally, Woodstock Corp bought a new position in Roche during the 3rd quarter valued at $245,000.

Key Headlines Impacting Roche

Here are the key news stories impacting Roche this week:

• Positive Sentiment: Roche agreed to a global licensing deal with China’s Rona Therapeutics for an ALK7-targeting RNAi therapy aimed at obesity and related metabolic diseases. The agreement could be worth up to $1.16 billion, strengthening Roche’s presence in the highly competitive obesity-drug market and adding a potential long-term growth asset. Roche strikes obesity drug licensing deal worth up to $1.16 billion with Chinese Rona Therapeutics
• Positive Sentiment: Roche reported positive Phase III results for vamikibart in uveitic macular edema, including sustained vision improvements, fewer retreatments and a favorable safety profile. The FDA has accepted the biologics license application, moving the drug closer to a potential U.S. launch and new revenue opportunity. Roche Reports Positive Phase III Data on Eye Drug, FDA Accepts BLA
• Neutral Sentiment: Brokerage analysts have a consensus target price of approximately $60 for Roche, implying potential upside from recent trading levels, although target prices are not guarantees of future performance. Roche Holding AG Stock Has Consensus Target Price of $60 According to Brokerages
• Negative Sentiment: Erste Group Bank reduced its Roche EPS forecasts to $3.05 for FY2026 from $3.14 and to $3.31 for FY2027 from $3.41. Although the revised FY2026 estimate remains slightly above the $3.03 consensus, the cuts signal softer expectations for near-term earnings growth.

Roche Company Profile

Roche Holding AG is a Swiss healthcare company headquartered in Basel, Switzerland. Founded in 1896, the company operates through two core divisions: Pharmaceuticals and Diagnostics. Roche develops medicines and diagnostic technologies intended to support disease prevention, detection, diagnosis and treatment.

Roche’s pharmaceutical activities focus on areas including oncology, immunology, neuroscience, ophthalmology, hematology and rare diseases. Its portfolio includes biologic and small-molecule medicines, as well as individualized healthcare approaches that use diagnostic information to help guide treatment decisions.

Through its Diagnostics division, Roche provides in vitro diagnostic systems, molecular testing, tissue-based diagnostics, diabetes-care products and laboratory solutions for healthcare providers, laboratories and patients.